Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Lenalidomide |
Synonyms | |
Therapy Description |
Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | mantle cell lymphoma | not applicable | Lenalidomide | FDA approved | Actionable | In a Phase II trial (EMERGE) that supported FDA approval, Revlimid (lenalidomide) treatment resulted in an objective response rate of 28% (37/134) with rapid time to response (2.2 months), a median duration of response of 16.6 months, a median progression-free survival of 4.0 months, and a median overall survival of 19.0 months in patients with mantle cell lymphoma who relapsed or progressed after or were refractory to Velcade (bortezomib) (PMID: 24002500; NCT00737529). | 24002500 detail... |
Unknown unknown | multiple myeloma | not applicable | Lenalidomide | Phase III | Actionable | In a Phase III trial, Revlimid (lenalidomide) maintenance treatment after stem cell transplant resulted in improved overall survival and progression free survival in patients with multiple myeloma (J Clin Oncol 35, 2017 (suppl; abstr 8037)). | detail... |
IKZF1 wild-type | multiple myeloma | sensitive | Lenalidomide | Preclinical | Actionable | In a preclinical study, Revlimid (lenalidomide) treatment resulted in IKZF1 degradation and decreased proliferation of multiple myeloma cells in culture (PMID: 24292625). | 24292625 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02030483 | Phase I | Palbociclib Dexamethasone Lenalidomide | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma | Terminated | USA | 0 |
NCT01954784 | Phase I | Bortezomib + Cyclosporine + Mycophenolate mofetil Lenalidomide | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma | Terminated | USA | 0 |
NCT03570892 | Phase III | Lenalidomide Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab Carmustine + Cytarabine + Etoposide + Melphalan Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cyclophosphamide + Fludarabine + Tisagenlecleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab Gemcitabine + Oxaliplatin + Rituximab Bendamustine + Fludarabine + Tisagenlecleucel | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA) | Recruiting | USA | 17 |
NCT03506802 | Phase I | Filgrastim + Plerixafor Lenalidomide Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Melphalan | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | Withdrawn | USA | 0 |
NCT01919086 | Phase II | Lenalidomide Bortezomib + Dexamethasone | Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT01459211 | Phase II | Dexamethasone Lenalidomide | Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) | Completed | 1 | |
NCT01604031 | Phase Ib/II | Lenalidomide | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide | Terminated | USA | 0 |
NCT04071457 | Phase III | Daratumumab + Lenalidomide + rHuPH20 Lenalidomide | S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC) | Recruiting | USA | 0 |
NCT04140162 | Phase II | Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide Daratumumab + Lenalidomide | Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy | Recruiting | USA | 0 |
NCT04430894 | Phase II | Carfilzomib + Dexamethasone + Isatuximab + Lenalidomide Carfilzomib + Isatuximab + Lenalidomide Lenalidomide | KRDI in Transplant-Eligible MM | Recruiting | USA | 0 |
NCT02579863 | Phase III | Pembrolizumab Dexamethasone Lenalidomide | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | Terminated | 0 | |
NCT02589145 | Phase Ib/II | Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | Terminated | USA | 0 |
NCT04196491 | Phase I | Lenalidomide bb2121 + Cyclophosphamide + Fludarabine | A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) (KarMMa-4) | Recruiting | USA | 0 |
NCT03901963 | Phase III | Daratumumab + Lenalidomide Lenalidomide | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA) | Recruiting | USA | 0 |
NCT02431208 | Phase I | Lenalidomide Atezolizumab | A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM) | Active, not recruiting | USA | 0 |
NCT01218555 | Phase I | Lenalidomide Everolimus | Study of Everolimus (RAD001)in Combination With Lenalidomide | Completed | USA | 0 |
NCT01729091 | Phase Ib/II | Dexamethasone Elotuzumab Filgrastim Melphalan Lenalidomide | Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma | Recruiting | USA | 0 |
NCT01827137 | Phase I | WT1 vaccine Lenalidomide Sargramostim | WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT01216683 | Phase II | Bendamustine + Rituximab Bortezomib Lenalidomide | Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma | Active, not recruiting | USA | 0 |
NCT02126553 | Phase II | Lenalidomide | Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | Recruiting | USA | 0 |
NCT03004287 | Phase II | Melphalan Carfilzomib Cisplatin Cyclophosphamide Lenalidomide Dexamethasone Daratumumab Bortezomib Etoposide Doxorubicin Thalidomide | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | Active, not recruiting | USA | 0 |
NCT01415752 | Phase II | Bortezomib Bendamustine Rituximab Lenalidomide | Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma | Active, not recruiting | USA | CAN | 0 |
NCT02213913 | Phase Ib/II | Lenalidomide Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | Recruiting | USA | 0 |
NCT01998971 | Phase I | Pomalidomide Bortezomib + Dexamethasone Melphalan Thalidomide Lenalidomide Prednisone Daratumumab Carfilzomib Diphenhydramine Montelukast | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | Active, not recruiting | USA | 2 |
NCT02265510 | Phase I | Gemcitabine Carfilzomib Dexamethasone Lenalidomide Nab-paclitaxel Azacitidine INCB052793 Bortezomib | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | Terminated | USA | 0 |
NCT02331368 | Phase II | Lenalidomide Melphalan Pembrolizumab | Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | Completed | USA | 0 |
NCT01556776 | Phase III | Lenalidomide | A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy | Active, not recruiting | 1 | |
NCT01863550 | Phase III | Dexamethasone Lenalidomide Carfilzomib Bortezomib | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 1 |
NCT03165734 | Phase II | Lenalidomide Ruxolitinib Hydroxyurea Pacritinib Thalidomide | A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) | Recruiting | USA | CAN | 17 |